Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Jun 9;330(3):679–686. doi: 10.1124/jpet.108.149807

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

U.S. Government work not protected by U.S. copyright

PMC Copyright notice

Fig. 3. — Intranasal DFO treatment reduces neurologic deficit score at 5 days or 48 h after middle cerebral artery occlusion (mean ± S.E.). Intranasal doses were administered under anesthesia. A, pretreatment with three 6-mg intranasal doses of 10% DFO (n = 9) compared with intranasally administered water control (n = 9). B, pretreatment with one 6-mg intranasal dose of 10% DFO (n = 14) compared with intranasally administered water control (n = 12). C, pretreatment with three 1.8-mg intranasal doses of 3% DFO (n = 14) compared with intranasally administered water control (n = 14). D, post-treatment with six 6-mg intranasal doses of 10% DFO (n = 9) compared with intranasally administered water control (n = 6). p values from Student's unpaired t test with #, p < 0.10 and *, p < 0.05.